Seromucinous tumors of the ovary. What's in a name?

International Journal of Gynecological Pathology

Volumn 35, Issue 1, 2016, Pages 78-81

  Kurman, Robert J ^a   Shih, Ie Ming ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borderline; Cancer; Ovarian; Seromucinous

Indexed keywords

CK20 PROTEIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN; RECEPTOR; RETINOBLASTOMA BINDING PROTEIN 2; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; WT1 PROTEIN; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

CLEAR CELL CARCINOMA; CLINICAL FEATURE; CYSTADENOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MIXED MULLERIAN ATYPICAL PROLIFERATIVE TUMOR; MIXED MULLERIAN CARCINOMA; MIXED MULLERIAN CYSTADENOMA; MIXED MULLERIAN TUMOR; MOLECULAR GENETICS; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEROMUCINOUS OVARIAN TUMOR; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; WORLD HEALTH ORGANIZATION; CLASSIFICATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

BIOMARKERS, TUMOR; ENDOMETRIOSIS; FEMALE; HUMANS; MIXED TUMOR, MULLERIAN; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84952715904     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000266     Document Type: Review

References (14)

1. Kurman RJ, Carcangiu ML, Herrington S, et al. WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon: IARC; 2014.
2. Fox H, Langley FA. Tumors of the Ovary. Chicago: William Heinemann/Year Book; 1976.
3. Rutgers JL, Scully RE. Ovarian müllerian mucinous cystadenomas of borderline malignancy. Cancer 1988;61:340-8.
4. Rutgers JL, Scully RE. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy. Cancer. 1988;61: 546-54.
5. Hendrickson MR, Kempson RL. Well differentiated mucinous neoplasms of the ovary. Pathology 1993;1:30734.
6. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002;26: 1529-41.
7. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. New Eng J Med 2010;363:1532-43.
8. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
9. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011;35:625-32.
10. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gyn Cancer 2012;22:1310-5.
11. Wu CH, Mao TL, Vang R, et al. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gyn Pathol 2012;31:297-303.
12. Kurman RJ, Shih I-M. The dualistic model of ovarian carcinogenesis. Revisited, revised and expanded. Am J. Pathol. (In press).
13. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 2006;25: 83-9.
14. Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 2015;39:983-92.